Dibutyrylmorphine

Dibutyrylmorphine
Clinical data
Routes of; administration	Oral, intravenous, intranasal, sublingual
ATC code	none;
Legal status
Legal status	AU: S8 (Controlled drug); CA: Schedule I; DE: Anlage I (Authorized scientific use only); UK: Class A;
Identifiers
	IUPAC name 7,8-Didehydro-4,5α-epoxy-17-methylmorphinan-3,6α-diol;
CAS Number	66641-03-0 ;
PubChem CID	5490372;
ChemSpider	4590341 ;
CompTox Dashboard (EPA)	DTXSID80985220 ;
Chemical and physical data
Formula	C25H31NO5
Molar mass	425.525 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)CCC)CCN3C;
	InChI InChI=1S/C25H31NO5/c1-4-6-20(27)29-18-10-8-15-14-17-16-9-11-19(30-21(28)7-5-2)24-25(16,12-13-26(17)3)22(15)23(18)31-24/h8-11,16-17,19,24H,4-7,12-14H2,1-3H3/t16-,17+,19-,24-,25-/m0/s1; Key:DOTAVBXFXPVSAS-OAQLGNTPSA-N;
	(what is this?)

Dibutyrylmorphine (also known as dibutanoylmorphine) is the 3,6-dibutyryl ester of morphine, first synthesized by the CR Alders Wright organization in the United Kingdom in 1875.^[1]

In animal studies its potency as an analgesic is higher compared to morphine, but lower than that of heroin.^[2]^[3]

Its structure is similar to that of other morphine esters such as heroin and nicomorphine. In many countries it is controlled as an ester of a controlled substance.

Esters of morphine were first produced by boiling morphine in acids or acid anhydrides including acetic, formic, propanoic, benzoic, butyric, and others, forming numerous mono-, di-, and tetraesters.^[1] Some of these were later researched further by others and some were eventually marketed.^[4] They included heroin, the first designer drugs which were produced in the late 1920s to replace heroin when it was outlawed by the League of Nations, medicinal drugs such as nicomorphine and others. Some of the corresponding esters of codeine, dihydrocodeine, dihydromorphine, isocodeine were also developed, such as the cough suppressant nicocodeine.^[5] The 3,6-diesters of morphine are drugs with more rapid and complete central nervous system penetration due to increased lipid solubility and other structural considerations.

References[edit]

^ ^a ^b National Research Council US; et al. (US Committee on drug addiction.) (1941). Report of Committee on Drug Addiction, 1929-1941 and Collected Reprints, 1930-1941. National Academies.
^ Tasker RA, Nakatsu K (April 1984). "Evaluation of 3,6-dibutanoylmorphine as an analgesic in vivo: comparison with morphine and 3,6-diacetylmorphine". Life Sciences. 34 (17): 1659–67. doi:10.1016/0024-3205(84)90637-4. PMID 6727542.
^ Tasker RA, Vander Velden PL, Nakatsu K (1984). "Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 8 (4–6): 747–50. doi:10.1016/0278-5846(84)90051-4. PMID 6543399. S2CID 23566872.
^ "Esters of Morphine Opioids". Archived from the original on 2023-02-13. Retrieved 2016-02-28.
^ Esters of Morphine, United Nations Office of Drug and Crime

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[rcda-1] National Research Council US; et al. (US Committee on drug addiction.) (1941). Report of Committee on Drug Addiction, 1929-1941 and Collected Reprints, 1930-1941. National Academies.

[2] Tasker RA, Nakatsu K (April 1984). "Evaluation of 3,6-dibutanoylmorphine as an analgesic in vivo: comparison with morphine and 3,6-diacetylmorphine". Life Sciences. 34 (17): 1659–67. doi:10.1016/0024-3205(84)90637-4. PMID 6727542.

[3] Tasker RA, Vander Velden PL, Nakatsu K (1984). "Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 8 (4–6): 747–50. doi:10.1016/0278-5846(84)90051-4. PMID 6543399. S2CID 23566872.

[4] "Esters of Morphine Opioids". Archived from the original on 2023-02-13. Retrieved 2016-02-28.

[5] Esters of Morphine, United Nations Office of Drug and Crime

[1]

[2]

[3]

[4]

[5]